Status:
COMPLETED
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Menopause
Hot Flashes
Eligibility:
FEMALE
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and al...
Eligibility Criteria
Inclusion
- Generally healthy, postmenopausal women who seek treatment for hot flushes
- Minimum of 7 moderate to severe hot flushes per day or 50 per week recorded for 7 consecutive days during screening
- Body Mass Index (BMI) less than or equal to 40 kg/m2
- Other inclusions apply.
Exclusion
- Hypersensitivity to Venlafaxine
- History of seizure disorder
- History of myocardial infarction or unstable angina within 6 months
- Other exclusions apply.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
568 Patients enrolled
Trial Details
Trial ID
NCT00256685
Start Date
September 1 2004
End Date
July 1 2005
Last Update
May 19 2006
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.